Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999725 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT01999725 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 80 participants.
The verdict
NCT01999725, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the safety of single doses of orally administered EDP-788. Secondary objectives of the study are: * To describe the pharmacokinetics of EDP-788 (and its metabolite EDP-322) after single doses of orally administered drug * To estimate the bioavailability of EDP-788 capsules relative to an oral liquid suspension * To estimate the effect of co-administration of food on the absorption of EDP-788
Interventions
- DRUG Placebo
- DRUG EDP-788
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01999725
The ClinicalTrials.gov registry entry for NCT01999725 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01999725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01999725 about?
NCT01999725 is a clinical study titled "Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788". The primary objective of the study is to determine the safety of single doses of orally administered EDP-788. Secondary objectives of the study are: * To describe the pharmacokinetics of EDP-788 (and its metabolite EDP-322) after single doses of orally administered drug * To estimate the bioavaila...
What is the current status of trial NCT01999725?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2014-01. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01999725?
The interventions under investigation include: Placebo (DRUG), EDP-788 (DRUG).
Who is sponsoring clinical trial NCT01999725?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.